84 results
8-K
EX-99.1
SRZN
Surrozen Inc
8 May 24
Surrozen Provides First Quarter 2024 Financial Results and Business Update
4:12pm
the limitations in pursuing the Wnt pathway as a therapeutic strategy.
About Surrozen
Surrozen is a clinical stage biotechnology company
8-K
EX-99.2
SRZN
Surrozen Inc
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
regeneration; attractive, novel treatment strategy for large markets with high unmet need First-in-class SZN-043 antibody in Phase 1 – Phase 1b dose … in normal and Fuchs’ diseased tissues Strategy: Wnt activation to regenerate corneal endothelial cells, reducing swelling & improving vision
8-K
EX-99.1
jiw31so5
1 Apr 24
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
8:52am
424B3
ogkh9xj1k
8 Nov 23
Prospectus supplement
4:27pm
8-K
EX-99.1
kkik9uymqzf60eafm
8 Nov 23
Surrozen Provides Third Quarter 2023 Financial Results
4:09pm
424B3
70ru9 7xhf76
9 Aug 23
Prospectus supplement
4:39pm
8-K
EX-99.1
5s5t4goy n8dgdzul1
9 Aug 23
Surrozen Provides Second Quarter 2023 Financial Results
4:16pm
424B3
uottc04s1xv 71l
10 May 23
Prospectus supplement
4:47pm
8-K
EX-99.1
t81u03rgtjyxv0
10 May 23
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
4:14pm
424B3
bcoht3 o0
7 Apr 23
Prospectus supplement
5:20pm
424B3
9riyq472 11
6 Apr 23
Prospectus supplement
5:15pm
POS AM
pxwlr
31 Mar 23
Prospectus update (post-effective amendment)
4:52pm
POS AM
3vtzzijz98or ldv
31 Mar 23
Prospectus update (post-effective amendment)
9:09am